RashDisease1 paperHuman trial1Trial sponsorsBritish Columbia Cancer Agency1 trialPhase 2150 peopleLatestLancet·25 NovEverolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyRandomised trial in 429 peoplemTOR inhibitorsPaper
Lancet·25 NovEverolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyRandomised trial in 429 peoplemTOR inhibitorsPaper